The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study CONSORT diagram. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Larger example of stimuli with cue relevant for Task 3. حسب Marcel F. Hinss (14675457)

DataSheet1_The OsGAPC3 mutation significantly affects grain quality traits and improves the nutritional quality of rice.docx حسب Bo Peng (273834)

"…The number and volume of type-II protein bodies in the endosperm of the OsGAPC3 mutants, and GPC increase significantly. We report significant increases in chalkiness area and degree, and decreases for starch content, gel consistency, and taste value. …"

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Demoralization Scale (DSII) by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

MXene/Bi₂O₃ Nanocomposites as Supercapacitors for Portable Electronic Devices حسب Nanasaheb M. Shinde (8560572)

الموضوعات:

Data Sheet 2_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... حسب Christopher L. Reading (21236861)

Data Sheet 1_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... حسب Christopher L. Reading (21236861)